 WAYNE, Pa., May 07, 2021 GLOBE NEWSWIRE -- Aclaris Therapeutics, Inc. NASDAQ: ACRS, a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2021 and provided a corporate update. 